BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12495648)

  • 1. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy.
    Nakken KO; Eriksson AS; Lossius R; Johannessen SI
    Seizure; 2003 Jan; 12(1):42-6. PubMed ID: 12495648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
    Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
    Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy.
    Grosso S; Franzoni E; Coppola G; Iannetti P; Verrotti A; Cordelli DM; Marchiani V; Pascotto A; Spalice A; Acampora B; Morgese G; Balestri P
    Seizure; 2005 Jun; 14(4):248-53. PubMed ID: 15911359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
    Grant R; Shorvon SD
    Epilepsy Res; 2000 Dec; 42(2-3):89-95. PubMed ID: 11074181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.
    Chaisewikul R; Privitera MD; Hutton JL; Marson AG
    Cochrane Database Syst Rev; 2001; (1):CD001901. PubMed ID: 11279737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience with levetiracetam in childhood epilepsy].
    Neuwirth M; Saracz J; Hegyi M; Paraicz E; Kollár K; Móser J; Rosdy B; Herczegfalvi A; Fogarasi A
    Ideggyogy Sz; 2006 May; 59(5-6):179-82. PubMed ID: 16786712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
    Ben-Menachem E; Gilland E
    Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial.
    Tonekaboni SH; Ghazavi M; Karimzadeh P; Mahvelati F; Ghofrani M
    Epilepsy Res; 2010 Aug; 90(3):273-7. PubMed ID: 20619606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of levetiracetam: a review of three pivotal clinical trials.
    Privitera M
    Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam in pediatrics.
    Vigevano F
    J Child Neurol; 2005 Feb; 20(2):87-93. PubMed ID: 15794171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levetiracetam in refractory pediatric epilepsy.
    Wheless JW; Ng YT
    J Child Neurol; 2002 Jun; 17(6):413-5. PubMed ID: 12174960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
    Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
    Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levetiracetam in refractory childhood epilepsy syndromes.
    Lagae L; Buyse G; Deconinck A; Ceulemans B
    Eur J Paediatr Neurol; 2003; 7(3):123-8. PubMed ID: 12788038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Levetiracetam in the treatment of epilepsy].
    Mariero Klees T; Brodtkorb E; Nakken KO; Lossius R; Johannessen SI
    Tidsskr Nor Laegeforen; 2003 May; 123(11):1539-41. PubMed ID: 12822020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
    Betts T; Waegemans T; Crawford P
    Seizure; 2000 Mar; 9(2):80-7. PubMed ID: 10845730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of levetiracetam efficacy in epileptic syndromes with continuous spikes-waves during slow sleep.
    Atkins M; Nikanorova M
    Seizure; 2011 Oct; 20(8):635-9. PubMed ID: 21752673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
    Li S; Cao J; Xiao N; Cai F
    J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.